New Alzheimer's drug repairs DNA damage and reduces brain inflammation

Researchers at King's College London have identified a promising new strategy for tackling Alzheimer's disease by targeting several of the disease's earliest biological changes at the same time. Their study found that KCL-286, an experimental drug originally developed for spinal cord injury that has already passed Phase 1 safety trials, reduced multiple hallmarks of Alzheimer's in a mouse model.

1. Homepage
2. Science
3. New Alzheimer's drug repairs DNA damage and reduces brain inflammation